blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3274333

EP3274333 - CABOZANTINIB SALTS AND THEIR USE AS ANTI-CANCER AGENTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.02.2020
Database last updated on 31.03.2026
FormerThe patent has been granted
Status updated on  22.03.2019
FormerGrant of patent is intended
Status updated on  14.11.2018
FormerRequest for examination was made
Status updated on  29.12.2017
FormerThe international publication has been made
Status updated on  02.08.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Sandoz AG
Lichtstrasse 35
4056 Basel / CH
[2018/05]
Inventor(s)01 / STEFINOVIC, Marijan
Sandoz GmbH
Biochemiestr. 10
6250 Kundl / AT
02 / SCHREINER, Erwin, Paul
Sandoz GmbH
Biochemiestr. 10
6250 Kundl / AT
 [2018/05]
Representative(s)Kluschanzoff, Harald, et al
Sandoz International GmbH
Global Intellectual Property
Industriestrasse 25
83607 Holzkirchen / DE
[2018/05]
Application number, filing date16711818.122.03.2016
[2018/05]
WO2016EP56262
Priority number, dateEP2015016087725.03.2015         Original published format: EP 15160877
[2018/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016150963
Date:29.09.2016
Language:EN
[2016/39]
Type: A1 Application with search report 
No.:EP3274333
Date:31.01.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 29.09.2016 takes the place of the publication of the European patent application.
[2018/05]
Type: B1 Patent specification 
No.:EP3274333
Date:24.04.2019
Language:EN
[2019/17]
Search report(s)International search report - published on:EP29.09.2016
ClassificationIPC:C07D215/22, A61K31/47, A61P35/00
[2018/05]
CPC:
A61K31/47 (EP,US); A61P35/00 (EP,US); C07D215/20 (EP,US);
C07D215/22 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/05]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:CABOZANTINIBSALZE UND IHRE VERWENDUNG ALS ANTIKREBSMITTEL[2018/49]
English:CABOZANTINIB SALTS AND THEIR USE AS ANTI-CANCER AGENTS[2018/05]
French:SELS DE CABOZANTINIBE ET LEUR APPLICATION EN TANT QU'AGENTS ANTI-CANCÉREUX[2018/49]
Former [2018/05]CABOZANTINIBSALZE UND DEREN VERWENDUNG ALS ANTIKREBSMITTEL
Former [2018/05]SELS DE CABOZANTINIB ET LEUR UTILISATION COMME AGENTS ANTI-CANCER
Entry into regional phase25.10.2017National basic fee paid 
25.10.2017Designation fee(s) paid 
25.10.2017Examination fee paid 
Examination procedure02.08.2017Date on which the examining division has become responsible
25.10.2017Examination requested  [2018/05]
22.03.2018Amendment by applicant (claims and/or description)
15.11.2018Communication of intention to grant the patent
14.02.2019Fee for grant paid
14.02.2019Fee for publishing/printing paid
14.02.2019Receipt of the translation of the claim(s)
Opposition(s)27.01.2020No opposition filed within time limit [2020/14]
Fees paidRenewal fee
13.03.2018Renewal fee patent year 03
13.03.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.03.2016
AL24.04.2019
AT24.04.2019
CY24.04.2019
CZ24.04.2019
DK24.04.2019
EE24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
MC24.04.2019
MK24.04.2019
MT24.04.2019
NL24.04.2019
PL24.04.2019
RO24.04.2019
RS24.04.2019
SE24.04.2019
SI24.04.2019
SK24.04.2019
SM24.04.2019
TR24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
IS24.08.2019
PT24.08.2019
[2022/32]
Former [2022/28]HU22.03.2016
AL24.04.2019
AT24.04.2019
CY24.04.2019
CZ24.04.2019
DK24.04.2019
EE24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
MC24.04.2019
MT24.04.2019
NL24.04.2019
PL24.04.2019
RO24.04.2019
RS24.04.2019
SE24.04.2019
SI24.04.2019
SK24.04.2019
SM24.04.2019
TR24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
IS24.08.2019
PT24.08.2019
Former [2020/50]AL24.04.2019
AT24.04.2019
CZ24.04.2019
DK24.04.2019
EE24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
MC24.04.2019
NL24.04.2019
PL24.04.2019
RO24.04.2019
RS24.04.2019
SE24.04.2019
SI24.04.2019
SK24.04.2019
SM24.04.2019
TR24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
IS24.08.2019
PT24.08.2019
Former [2020/26]AL24.04.2019
AT24.04.2019
CZ24.04.2019
DK24.04.2019
EE24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
NL24.04.2019
PL24.04.2019
RO24.04.2019
RS24.04.2019
SE24.04.2019
SI24.04.2019
SK24.04.2019
SM24.04.2019
TR24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
IS24.08.2019
PT24.08.2019
Former [2020/17]AL24.04.2019
AT24.04.2019
CZ24.04.2019
DK24.04.2019
EE24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
NL24.04.2019
PL24.04.2019
RO24.04.2019
RS24.04.2019
SE24.04.2019
SK24.04.2019
SM24.04.2019
TR24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
IS24.08.2019
PT24.08.2019
Former [2020/14]AL24.04.2019
AT24.04.2019
CZ24.04.2019
DK24.04.2019
EE24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
NL24.04.2019
PL24.04.2019
RO24.04.2019
RS24.04.2019
SE24.04.2019
SK24.04.2019
SM24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
IS24.08.2019
PT24.08.2019
Former [2020/11]AL24.04.2019
AT24.04.2019
CZ24.04.2019
DK24.04.2019
EE24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
NL24.04.2019
PL24.04.2019
RO24.04.2019
RS24.04.2019
SE24.04.2019
SK24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
IS24.08.2019
PT24.08.2019
Former [2020/10]AL24.04.2019
AT24.04.2019
CZ24.04.2019
DK24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
NL24.04.2019
PL24.04.2019
RO24.04.2019
RS24.04.2019
SE24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
IS24.08.2019
PT24.08.2019
Former [2020/09]AL24.04.2019
CZ24.04.2019
DK24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
NL24.04.2019
PL24.04.2019
RS24.04.2019
SE24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
IS24.08.2019
PT24.08.2019
Former [2020/04]AL24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
NL24.04.2019
PL24.04.2019
RS24.04.2019
SE24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
IS24.08.2019
PT24.08.2019
Former [2019/52]AL24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
NL24.04.2019
PL24.04.2019
RS24.04.2019
SE24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
PT24.08.2019
Former [2019/51]AL24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
NL24.04.2019
RS24.04.2019
SE24.04.2019
BG24.07.2019
NO24.07.2019
GR25.07.2019
PT24.08.2019
Former [2019/50]AL24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
LV24.04.2019
NL24.04.2019
RS24.04.2019
SE24.04.2019
NO24.07.2019
GR25.07.2019
PT24.08.2019
Former [2019/49]AL24.04.2019
FI24.04.2019
HR24.04.2019
LT24.04.2019
NL24.04.2019
SE24.04.2019
NO24.07.2019
PT24.08.2019
Former [2019/48]FI24.04.2019
LT24.04.2019
NL24.04.2019
SE24.04.2019
NO24.07.2019
PT24.08.2019
Former [2019/47]FI24.04.2019
LT24.04.2019
NL24.04.2019
NO24.07.2019
Former [2019/44]NL24.04.2019
Cited inInternational search[A]   DATABASE WPI 22 October 2014 Derwent World Patents Index; AN 2015-02455E, XP002742129, MENG QINGYI ET AL.: "Cabozantinib 0.5 malate crystals used for preparing drug composition for treating tumor exhibit X-Ray powder diffraction pattern with peaks given in the specification" [A] 1-10 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.